With just one jab, people in Europe will soon be able to protect themselves against two of the most widespread respiratory diseases – something that is unlikely to happen in the US under the current health secretary.
This Friday, the European Medicines Agency (EMA) recommended the approval of the novel combination vaccine mCombriax from US manufacturer Moderna against influenza and Covid-19 for adults aged 50 and over.
This makes it very likely that the European Commission will soon approve the mRNA-based vaccine for the EU market. Member states and Moderna will then negotiate the price of the vaccine.
The vaccine would be the first ever to protect people against both influenza and COVID-19. Both infectious diseases primarily affect the respiratory tract. According to the EMA, up to 50 million people in Europe contract influenza alone each year.
Combination vaccines have been used for years to protect against other diseases such as measles, mumps and rubella. They require fewer visits to the doctor and reduce vaccination stress for patients.
First combined COVID-19 and influenza vaccine for people 50 years and older